Age: 18 - 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Novo Nordisk A/S
Prior Safety Data
Trial Summary
What is the purpose of this trial?This trial tests semaglutide in different doses to see how well it controls blood sugar and weight in people with type 2 diabetes who are overweight and taking metformin. The medicine is given as an injection under the skin. Semaglutide has been studied extensively for its effectiveness in controlling blood sugar and weight in type 2 diabetes, and it is available in both injectable and oral forms.
Eligibility Criteria
Treatment Details
6Treatment groups
Experimental Treatment
Placebo Group
Group I: Semaglutide 8 mgExperimental Treatment1 Intervention
Participants will receive once-weekly semaglutide 8 mg s.c. injection.
Group II: Semaglutide 2 mgExperimental Treatment1 Intervention
Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.
Group III: Semaglutide 16 mgExperimental Treatment1 Intervention
Participants will receive once-weekly semaglutide 16 mg s.c. injection.
Group IV: Semaglutide placebo 2 mgPlacebo Group1 Intervention
Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.
Group V: Semaglutide placebo 8 mgPlacebo Group1 Intervention
Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.
Group VI: Semaglutide placebo 16 mgPlacebo Group1 Intervention
Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Novo Nordisk Investigational SiteMeridian, ID
Novo Nordisk Investigational SiteLexington, KY
Novo Nordisk Investigational SiteLos Angeles, CA
Novo Nordisk Investigational SiteSan Mateo, CA
More Trial Locations
Loading ...
Who is running the clinical trial?
Novo Nordisk A/SLead Sponsor